Alzheimer’s disease (AD): lecanemab treatment

Evidence-based neurology checklist on alzheimer’s disease (ad): lecanemab treatment: General This is a monoclonal antibody It is indicated in early AD It moderately improves cognition, function and behaviour It reduces markers of amyloid Eligibility Administration Adverse effects Stopping…

General

  • This is a monoclonal antibody
  • It is indicated in early AD
  • It moderately improves cognition, function and behaviour
  • It reduces markers of amyloid

Eligibility

Administration

Adverse effects

Stopping indications

References

  1. Mummery CJ, Rasmussen J, Blackburn D, et al. Lecanemab appropriate use recommendations for clinical practice in the UK. JNNP 2026; 97:372-384.
  2. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023; 388:9-21.
  3. Qiao Y, Chi Y, Zhang Q, Ma Y. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci 2023; 15:1169499.
  4. Schwartz NU, Dietz CD, Prufer Araújo I, et al. Changes of a cerebral cavernous malformation associated with lecanemab therapy in a patient with Alzheimer disease. Neurol Clin Pract 2025; 15:e200508.
  5. Paczynski M, Hofmann A, Posey Z, et al. Lecanemab treatment in a specialty memory clinic. JAMA Neurol 2025; 82:655-665.

Related checklists

Loading...